Merck & Company Inc (MRK)vsPAVmed Inc (PAVM)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
PAVM
PAVmed Inc
$8.30
-6.95%
HEALTHCARE · Cap: $61.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 91564687% more annual revenue ($65.01B vs $71,000). PAVM leads profitability with a 565.0% profit margin vs 28.1%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
PAVM
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Intrinsic value data unavailable for PAVM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Keeps 565 of every $100 in revenue as profit
Revenue surging 420.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -32.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : PAVM
The strongest argument for PAVM centers on Price/Book, Profit Margin, Revenue Growth. Profitability is solid with margins at 565.0% and operating margin at -13083.0%. Revenue growth of 420.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : PAVM
The primary concerns for PAVM are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while PAVM is a growth play — different risk/reward profiles.
PAVM carries more volatility with a beta of 0.81 — expect wider price swings.
PAVM is growing revenue faster at 420.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 31/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →PAVmed Inc
HEALTHCARE · MEDICAL DEVICES · USA
PAVmed Inc. is a medical device company in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?